RecruitingNCT06570967

A Clinical Study of Hyperthyroidism in Children

A Retrospective and Prospective Observational Study of Hyperthyroidism in Children


Sponsor

Shengjing Hospital

Enrollment

1,000 participants

Start Date

Jul 18, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This study intends to conduct a retrospective and prospective study on children with hyperthyroidism, and it is a non-intervention study to collect information on diagnosis and treatment and long-term follow-up of children with hyperthyroidism. To investigate the clinical characteristics, treatment effect, side effects and remission of hyperthyroidism in children, to analyze the predictive factors for the effect of antithyroid drug treatment, remission and recurrence after drug withdrawal, and to explore the risk factors related to the occurrence of antithyroid drug-related adverse reactions.


Eligibility

Min Age: 29 DaysMax Age: 14 Years

Inclusion Criteria2

  • Age ≤14 years old
  • Initial diagnosis of hyperthyroidism

Exclusion Criteria3

  • Hyperthyroidism had been treated with medication in other hospitals,
  • History of autoimmune hepatitis, viral hepatitis, hematological diseases, bone marrow or liver transplantation,
  • Patients with incomplete clinical data

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethimazole(MMI)

The initial dose of methimazole was 0.2-0.8 mg/(kg▪d). This dose was subsequently reduced by 25% to 50% and adjusted to maintain euthyroidism, based on the results of serum thyroid hormone testing during follow-up.


Locations(1)

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06570967


Related Trials